INVESTIGATIONAL NEW DRUGS

简称 INVEST NEW DRUG ·UNITED STATES ·出版周期 Quarterly ·年均收录 88 篇

2.7

最新影响因子

2.70%

自引率

较易

投稿难度

平均1.0个月

审稿周期

期刊简介

INVESTIGATIONAL NEW DRUGS是一本专注于新药研发领域的国际学术期刊，ISSN号为0167-6997，由美国出版商Springer出版，出版地为美国，出版周期为双月刊。该期刊的影响因子根据最新数据约为2.5左右，属于非开放获取（非OA）期刊，并被SCI收录，在中科院分区中通常位于医学或药学领域的3区或4区。该杂志的发文特点主要集中在临床前和临床阶段的抗肿瘤药物研究，涵盖药物发现、药理学、毒理学及临床试验等领域，尤其关注创新药物的开发与评价。杂志的质量较高，审稿流程严格，但影响因子相对中等，可能存在投稿竞争激烈和发表周期较长的风险，适合从事新药研发的研究人员投稿。

影响因子趋势

近期发表

Parthenolide enhances imatinib activity in gastrointestinal stromal tumor models through stress-associated apoptosis 2026-09-15

First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors 2026-09-14

Qishen Yiqi Dripping Pills ameliorate doxorubicin-induced cardiotoxicity: a study based on bioinformatics and experimental verification 2026-08-28

Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study 2026-08-28

Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer 2026-08-27

Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence 2026-07-23

The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells 2026-07-17

Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database 2026-07-10

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors 2026-07-07

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study 2026-06-22